Navigation Links
Romosozumab signif increases bone mineral density and bone content compared with teriparatide
Date:6/11/2014

A new study presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) shows that in postmenopausal women with low bone mass, romosozumab significantly increased bone mineral density and bone content in both the spine and hip compared to baseline, and also compared with the commonly prescribed anabolic agent teriparatide and placebo.1

Romosozumab, administered subcutaneously at monthly intervals over a period of 12 months, resulted in gains in both the trabecular* and cortical compartments of the spine and hip regions, with important differences between romosozumab and teriparatide observed depending on the skeletal location.

"These impressive results support the continued clinical investigation of romosozumab as a potential treatment for postmenopausal women with osteoporosis with established bone mineral density deficit who are at increased risk of fracture," said lead investigator Professor Harry K. Genant of the University of California San Francisco, and a Co-founder of Synarc, Inc. the world's largest imaging core lab dedicated to clinical trials.

"A large phase III clinical trial program is underway, evaluating romosozumab against both placebo and an active comparator in more than 10,000 women with postmenopausal osteoporosis to evaluate its potential to prevent osteoporotic fractures, and to confirm its safety for long-term use," Professor Genant added.

In the lumbar spine, treatment with romosozumab and teriparatide achieved similar and significant gains from baseline in trabecular bone mineral density +18.3% vs. +20.1% respectively p<0.05).

However, at the hip, trabecular bone mineral density gains were significantly larger with romosozumab than teriparatide (10.8% vs 4.2%, P=0.01). Cortical bone mineral density gains were larger with romosozumab compared with teriparatide at both the lumbar spine (13.7% vs. 5.7%, P<0.0001) and hip (1.1% vs. 𔂾.9%, P=0.12). Cortical bone
'/>"/>

Contact: EULAR Press Office
eularpressoffice@cohnwolfe.com
44-078-801-73209
European League Against Rheumatism
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Reduced neurosurgical resident hours: No significant positive effect on patient outcomes
2. Survey finds significant gap in detection of malnutrition in Canadian hospital patients
3. Phase III clinical trial shows image fusion-guided biopsy significantly improves accuracy of prostate
4. Little exercise and heavy use of electronic media constitute a significant health risk for children
5. Water pipe smoking causes significant exposure to nicotine and cancer-causing agents
6. Significant differences in CVD risk factors between men and women with type 2 diabetes
7. Image-guided peritoneal dialysis catheter placement significantly reduces complications
8. New genome-editing platform significantly increases accuracy of CRISPR-based systems
9. Ankle fractures could be significant risk factor for subsequent fracture
10. Researchers find significant increase in painkillers prescribed to US adults in the ER
11. Physical activity significantly extends lives of cancer survivors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2015)... In recent years Medical Marijuana has continuously been ... a way for them to expand their patient base without ... Since the FDA still lists Cannabis as a Schedule 1 ... physicians that can help guide them when recommending a ... in Santa Cruz, CA is a leader in the small, ...
(Date:2/28/2015)... AB (PRWEB) February 28, 2015 The ... is now a distributor of the machine. The Heart ... of their license, like a franchise model. The goal ... prevent and reverse heart disease. To buy External ... Fit Clinic can help individuals through this process and ...
(Date:2/28/2015)... NB (PRWEB) February 28, 2015 ... center software suite for Asterisk, are pleased to announce ... highly successful 5.7 and 5.8 versions of Q-Suite, this ... well as a number of new features to the ... Q2 2015. , Q-Suite 5.9 will add features to ...
(Date:2/28/2015)... 28, 2015 National Sales ... sales, marketing and supply chain management for consumer ... is bringing its award winning solutions for thinning-damaged ... products are specifically created to combat thinning-damaged hair. ... is committed to marrying science with nature to ...
(Date:2/28/2015)... 28, 2015 How would you ... , There are all kinds of different leaders, ... awareness of the advantages and applications of different ... launching a new product this spring called The ... the connection between personality type, leadership, and success. ...
Breaking Medicine News(10 mins):Health News:Reputable Cannabis Doctor In Santa Cruz and Monterey Joins the Medical Cannabis Network 2Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Indosoft Proudly Announces Q-Suite 5.9 Call Center Software for Asterisk 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3Health News:PeopleKeys Launches The Leadership Report 2Health News:PeopleKeys Launches The Leadership Report 3
... be "alarmingly dismal" with over 180 million urban poor having ... an industry analysis. ,At least 300 additional urban ... annually to cater to the needs of 215 million urban ... of Commerce and Industry of India (ASSOCHAM). ,In ...
... of colorectal cancers getting missed out in patients undergoing ... a gastroenterologist// or a surgeon. This was disclosed by ... researchers. ,This study was conducted on 12,487 ... Ontario along with her team. According to this study, ...
... flu in their county. This was disclosed by Faizullah Kakar, ... H5N1 virus was found in the eastern province of Nangarhar. ... diagnosed as the case of malaria. The Nangarhar area has ... ,Culling of birds was initiated earlier this week ...
... risk of mercury in canned albacore tuna in women and ... tuna in women and children. This follows a recent report ... cans of albacore tuna tested contained mercury more than the ... of canned albacore tuna per week can be had by ...
... and intolerance to gluten.// ,Inflammatory ... inflammations in muscular tissue. Coeliac disease is ... ,Inflammatory myopathies are inflammatory infiltrates ... includes polymyositis, dermatomyositis, and inclusion-body myositis. Little ...
... the heart gets its distinguishing shape? Shape may be formed ... and shape, all of which react to// influences from the ... bulges later on to develop into cardiac chambers. ... journal PLoS Biology, Heidi Auman, Deborah Yelon, and colleagues found, ...
Cached Medicine News:Health News:Urban Poor in Dire Need of Proper Healthcare: Report 2Health News:Inflammatory Myopathy may Indicate Intolerance to Gluten 2
(Date:2/27/2015)... , February 27, 2015 Report ... study showing you trends, R&D progress, and predicted revenues ... heading? What are the commercial prospects for this market ... potential revenues and other trends to 2025, discussing data, ... lets you assess regenerative medicine : cell-based therapies ...
(Date:2/27/2015)... 27, 2015 /CNW/ - Covalon Technologies Ltd. (the "Company" or ... announced financial results for its first quarter ended December ... ended December 31, 2014, revenue was $1,336,685. Operating expenses ... or $0.02 per share.  Covalon,s President ... very pleased with the significant progress we have made ...
(Date:2/27/2015)... TEL-AVIV, Israel , February 27, 2015 ... Unternehmen baut sein bahnbrechendes Überwachungssystem für kongestive ... weiter aus -   ... Medical Technologies, die ein neuartiges Herzüberwachungssystem für ... gab heute bekannt, dass sie ein Finanzierungsvorhaben ...
Breaking Medicine Technology:Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8Covalon Announces First Quarter Financial Results 2Covalon Announces First Quarter Financial Results 3Vectorious Medical Technologies schließt Finanzierungsvorhaben über 5 Mio. USD ab 2
... Silence Therapeutics plc (AIM: SLN) ("Silence" or ... its ongoing research and development collaboration with AstraZeneca.  Under the ... signed in July 2007 , Silence and AstraZeneca are ... siRNA therapeutic molecules addressing respiratory and oncology indications. , ...
... Medical Tactile, Inc. and Valentus Medical Technologies, Inc. ... , Canada , has signed a partnership agreement with Medical Tactile, ... SureTouch™ , the non-invasive digital breast imaging technology, worldwide, with the ... , , ...
Cached Medicine Technology:Silence Therapeutics and AstraZeneca Extend siRNA Development Collaboration 2Silence Therapeutics and AstraZeneca Extend siRNA Development Collaboration 3Partnership Brings Breast Image Documentation Technology to Women Around the World 2
Donor Screen & Confirmation Kit...
... method for Dimension integrated chemistry systems ... in vitro diagnostic test intended to ... (TPSA) in human serum or plasma. ... in the detection of prostate cancer ...
... Wampole Laboratories offers a comprehensive line of ... serum and urine in convenient one-step stick ... 2 testing options. Clearview Easy HCG is ... convenient stick format. Clearview HCG II ...
The BioCheck hCG ELISA is intended for the quantitative determination of human chorionic gonadotropin (hCG) concentration in human serum. The assay is for use in the early diagnosis of pregnancy in a...
Medicine Products: